The QH103E therapy represents a novel approach in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) by utilizing allogeneic γδT cells engineered to express a CD19-targeting CAR. The market for CAR T-cell therapies is rapidly expanding, with significant demand for innovative treatments in hematological malignancies. Given the increasing prevalence of NHL and the limitations of existing therapies, QH103E could capture a substantial share of this market if proven effective and safe. Competitive analysis indicates that while there are established players in the CAR T-cell space, the unique mechanism of action and potential for enhanced memory efficacy may provide a differentiated position. Diligence should focus on the regulatory pathway, potential partnerships, and reimbursement strategies, particularly in the context of the Chinese healthcare system.